These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30808623)

  • 21. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
    Bergstra SA; Landewé RBM; Huizinga TWJ; Allaart CF
    Rheumatology (Oxford); 2017 Oct; 56(10):1721-1728. PubMed ID: 28957556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.
    Schipper LG; Vermeer M; Kuper HH; Hoekstra MO; Haagsma CJ; Den Broeder AA; van Riel P; Fransen J; van de Laar MA
    Ann Rheum Dis; 2012 Jun; 71(6):845-50. PubMed ID: 22210852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study.
    Maillefert JF; Combe B; Goupille P; Cantagrel A; Dougados M
    Ann Rheum Dis; 2003 Aug; 62(8):764-6. PubMed ID: 12860733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Möttönen T; Hannonen P; Korpela M; Nissilä M; Kautiainen H; Ilonen J; Laasonen L; Kaipiainen-Seppänen O; Franzen P; Helve T; Koski J; Gripenberg-Gahmberg M; Myllykangas-Luosujärvi R; Leirisalo-Repo M;
    Arthritis Rheum; 2002 Apr; 46(4):894-8. PubMed ID: 11953964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial.
    Lucassen MJJ; Ter Wee MM; den Uyl D; Konijn NPC; Nurmohamed MT; Voskuyl AE; van Schaardenburg D; Kerstens PJSM; Bultink IEM; Boers M; Lems WF
    Osteoporos Int; 2021 Jul; 32(7):1441-1449. PubMed ID: 33464392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis.
    Boers M; Kostense PJ; Verhoeven AC; van der Linden S;
    Arthritis Rheum; 2001 Oct; 44(10):2242-6. PubMed ID: 11665964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks.
    den Uyl D; ter Wee M; Boers M; Kerstens P; Voskuyl A; Nurmohamed M; Raterman H; van Schaardenburg D; van Dillen N; Dijkmans B; Lems W
    Ann Rheum Dis; 2014 Jun; 73(6):1071-8. PubMed ID: 23606682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.
    Karstila KL; Rantalaiho VM; Mustonen JT; Möttönen TT; Hannonen PJ; Leirisalo-Repo M; Kaipiainen-Seppänen OA; Karjalainen AH; Korpela MM;
    Clin Exp Rheumatol; 2010; 28(1):73-8. PubMed ID: 20346242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
    van Rossum MA; van Soesbergen RM; Boers M; Zwinderman AH; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA;
    Ann Rheum Dis; 2007 Nov; 66(11):1518-24. PubMed ID: 17491099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone.
    Verhoeven AC; Boers M; te Koppele JM; van der Laan WH; Markusse HM; Geusens P; van der Linden S
    Rheumatology (Oxford); 2001 Nov; 40(11):1231-7. PubMed ID: 11709606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
    Kuusalo L; Puolakka K; Kautiainen H; Blåfield H; Eklund KK; Ilva K; Kaipiainen-Seppänen O; Karjalainen A; Korpela M; Valleala H; Leirisalo-Repo M; Rantalaiho V;
    Scand J Rheumatol; 2015; 44(6):449-55. PubMed ID: 26324784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
    Garnero P; Landewé R; Boers M; Verhoeven A; Van Der Linden S; Christgau S; Van Der Heijde D; Boonen A; Geusens P
    Arthritis Rheum; 2002 Nov; 46(11):2847-56. PubMed ID: 12428224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
    Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
    Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
    Akdemir G; Heimans L; Bergstra SA; Goekoop RJ; van Oosterhout M; van Groenendael JHLM; Peeters AJ; Steup-Beekman GM; Lard LR; de Sonnaville PBJ; Grillet BAM; Huizinga TWJ; Allaart CF
    Ann Rheum Dis; 2018 Jan; 77(1):111-118. PubMed ID: 28970207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.